Intra-Cellular Therapies, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Intra-Cellular Therapies, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2012 to Q3 2024.
  • Intra-Cellular Therapies, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $146M, a 41.8% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $146M +$42.9M +41.8% Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $146M +$49.8M +51.8% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $131M +$49.6M +60.8% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $114M +$38.8M +51.6% Dec 31, 2023 10-Q 2024-10-30
Q3 2023 $103M +$41.1M +66.8% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $96M +$49M +104% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $81.5M +$48.7M +148% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $75.2M +$55M +273% Dec 31, 2022 10-K 2024-02-22
Q3 2022 $61.5M +$44.6M +263% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $47M +$31.8M +209% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $32.8M +$19.2M +140% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $20.2M +$9.39M +87.2% Dec 31, 2021 10-K 2023-03-01
Q3 2021 $16.9M +$9.45M +126% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $15.2M +$12.8M +545% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $13.7M +$12.3M +911% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $10.8M Dec 31, 2020 10-K 2022-03-01
Q3 2020 $7.48M Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $2.35M Jun 30, 2020 10-Q 2020-08-10
Q1 2020 $1.35M Mar 31, 2020 10-Q 2020-05-07
Q3 2017 $6.31K +$5K Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $61.9K -$36.3K -37% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $68.2K +$68.2K Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $94.3K +$63.7K +208% Dec 31, 2016 10-K 2018-03-01
Q3 2016 $1.31K* Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $98.2K +$89.1K +977% Jun 30, 2016 10-Q 2016-08-04
Q1 2016 $0 -$3.32K Mar 31, 2016 10-Q 2016-04-28
Q4 2015 $30.7K -$20.9K -40.6% Dec 31, 2015 10-K 2017-03-01
Q2 2015 $9.12K -$210K -95.8% Jun 30, 2015 10-Q 2015-08-05
Q1 2015 $3.32K* -$164K Mar 31, 2015 10-Q 2015-04-30
Q4 2014 $51.6K -$285K -84.7% Dec 31, 2014 10-K 2016-02-25
Q3 2014 $124K -$127K -50.5% Sep 30, 2014 10-Q 2014-11-03
Q2 2014 $219K Jun 30, 2014 10-Q 2014-08-12
Q1 2014 $168K Mar 31, 2014 10-Q 2014-05-05
Q4 2013 $336K +$35.9K +11.9% Dec 31, 2013 10-K 2015-03-12
Q3 2013 $251K Sep 30, 2013 10-Q 2013-11-05
Q4 2012 $300K Dec 31, 2012 10-K 2014-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.